Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $10.77 USD
Change Today -0.29 / -2.62%
Volume 729.0K
NKTR On Other Exchanges
As of 8:10 PM 04/24/15 All times are local (Market data is delayed by at least 15 minutes).

Executive Profile*

Gil M. Labrucherie J.D.

Senior Vice President, General Counsel and Secretary, Nektar Therapeutics
AgeTotal Calculated CompensationThis person is connected to 0 board members in 0 different organizations across 3 different industries.

As of Fiscal Year 2013


Mr. Gil M. Labrucherie, J.D. has been General Counsel and Senior Vice President of Nektar Therapeutics since April 2, 2007. Mr. Labrucherie has been Secretary of Nektar Therapeutics since April 2, 2007. He serves as Secretary of Senova Systems, Inc. He served as Interim Secretary of Chadmoore Wireless Group Inc. (formerly, Capvest Internationale Ltd.) since November 10, 2006 and as its Interim President from November 10, 2006 to March 26, 2007. Mr. Labrucherie served ...

Read Full Background

Corporate Headquarters*

455 Mission Bay Boulevard South
San Francisco, California 94158

United States

Phone: 415-482-5300
Fax: 415-339-5300

Board Members Memberships*

Co-Founder and Secretary
Former Chairman and Interim Secretary


University of California, Davis
University of California-berkeley School of Law

Other Affiliations*

Annual Compensation*

Total Annual Compensation$504,195

Stock Options*

All Other Compensation$7,238
Exercisable Options889,150
Exercisable Options Value$3,357,338
Unexercisable Options231,250
Unexercisable Options Value$656,563
Total Value of Options$4,013,900
Total Number of Options1,120,400

Total Compensation*

Total Annual Cash Compensation$789,433
Total Short Term Compensation$504,195
Other Long Term Compensation$7,238
Total Calculated Compensation$1,478,488
*Data is at least as current as the most recent Definitive Proxy.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NKTR:US $10.77 USD -0.29


Michael W. Aguiar Chief Executive Officer, President and Director
Theravance Inc.
Peter M. Hecht Ph.D. Co-Founder, Chief Executive Officer and Director
Ironwood Pharmaceuticals, Inc.
James A. Schoeneck Chief Executive Officer, President and Director
DepoMed Inc.
Peter S. Greenleaf Chief Executive Officer and Director
Sucampo Pharmaceuticals, Inc.
Daniel J. Abdun-Nabi Chief Executive Officer, President, Director, Member of Strategic Operations Committee and Member of Pricing Committee
Emergent BioSolutions, Inc.
Compensation as of Fiscal Year 2014.

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NEKTAR THERAPEUTICS, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at